Laboratory Corporation of America Holdings (LH) Income Statement Analysis

See more : Adeka Corporation (ADKCF) Income Statement Analysis – Financial Results

Complete financial analysis of Laboratory Corporation of America Holdings (LH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Laboratory Corporation of America Holdings, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

Laboratory Corporation of America Holdings (LH)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.labcorp.com

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988
Revenue	12.16B	14.88B	16.12B	13.98B	11.55B	11.33B	10.44B	9.64B	8.68B	6.01B	5.81B	5.67B	5.54B	5.00B	4.69B	4.51B	4.07B	3.59B	3.33B	3.08B	2.94B	2.51B	2.20B	1.92B	1.70B	1.61B	1.52B	1.61B	1.43B	872.50M	760.50M	721.40M	603.90M	501.90M	402.40M	313.90M
Cost of Revenue	8.80B	10.49B	10.50B	9.03B	8.30B	8.16B	6.98B	6.46B	5.78B	3.81B	3.59B	3.42B	3.27B	2.91B	2.72B	2.63B	2.38B	2.06B	1.94B	1.80B	1.71B	1.45B	1.27B	1.10B	1.02B	995.80M	1.02B	1.13B	978.90M	568.90M	421.40M	376.50M	310.50M	260.90M	211.30M	0.00
Gross Profit	3.36B	4.39B	5.62B	4.95B	3.25B	3.18B	3.46B	3.18B	2.90B	2.20B	2.22B	2.25B	2.27B	2.10B	1.97B	1.87B	1.69B	1.53B	1.39B	1.29B	1.22B	1.06B	925.60M	822.70M	682.40M	616.80M	494.70M	478.70M	453.10M	303.60M	339.10M	344.90M	293.40M	241.00M	191.10M	313.90M
Gross Profit Ratio	27.67%	29.48%	34.89%	35.43%	28.15%	28.03%	33.18%	32.99%	33.45%	36.65%	38.28%	39.67%	41.04%	41.92%	41.98%	41.59%	41.57%	42.59%	41.78%	41.80%	41.66%	42.34%	42.08%	42.86%	40.17%	38.25%	32.57%	29.78%	31.64%	34.80%	44.59%	47.81%	48.58%	48.02%	47.49%	100.00%
Research & Development	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	516.50M	483.00M	448.20M	405.00M	499.90M	490.00M	313.50M	149.30M	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	2.02B	2.00B	1.95B	1.73B	1.62B	1.57B	1.81B	1.63B	1.62B	1.20B	1.13B	1.11B	1.16B	1.03B	958.90M	935.10M	808.70M	779.10M	703.90M	649.10M	651.80M	585.50M	516.50M	483.00M	448.20M	405.00M	499.90M	490.00M	313.50M	149.30M	121.40M	117.90M	97.90M	82.20M	65.00M	0.00
Other Expenses	0.00	259.30M	369.60M	275.40M	243.20M	167.70M	-7.60M	2.60M	-7.80M	10.40M	2.10M	-7.20M	85.80M	72.70M	62.60M	57.90M	54.90M	52.20M	51.40M	42.70M	37.60M	23.80M	41.50M	89.60M	84.50M	84.20M	86.80M	84.50M	72.40M	44.40M	32.20M	26.90M	22.00M	18.40M	13.30M	0.00
Operating Expenses	2.02B	2.26B	2.32B	2.00B	1.87B	1.80B	2.03B	1.81B	1.79B	1.27B	1.21B	1.20B	1.25B	1.11B	1.02B	1.03B	863.60M	831.30M	755.30M	691.80M	689.40M	609.30M	558.00M	572.60M	532.70M	489.20M	586.70M	574.50M	385.90M	193.70M	153.60M	144.80M	119.90M	100.60M	78.30M	0.00
Cost & Expenses	11.44B	12.75B	12.82B	11.03B	10.17B	9.96B	9.01B	8.27B	7.56B	5.08B	4.80B	4.62B	4.51B	4.01B	3.75B	3.66B	3.24B	2.89B	2.69B	2.49B	2.40B	2.06B	1.83B	1.67B	1.55B	1.49B	1.61B	1.70B	1.36B	762.60M	575.00M	521.30M	430.40M	361.50M	289.60M	0.00
Interest Income	0.00	8.90M	10.20M	10.30M	8.80M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.30M	1.10M	1.60M	2.50M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	199.60M	180.30M	212.10M	207.40M	240.70M	244.20M	235.10M	219.10M	274.90M	109.50M	103.70M	94.50M	87.50M	70.00M	62.90M	72.00M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	577.30M	537.20M	940.00M	825.00M	771.30M	552.10M	533.20M	490.60M	457.80M	245.50M	81.70M	86.30M	85.80M	72.70M	62.60M	57.90M	162.80M	155.00M	149.80M	138.80M	135.60M	101.80M	104.00M	89.60M	84.50M	84.20M	86.80M	84.50M	72.40M	44.40M	32.20M	26.90M	22.00M	18.40M	13.30M	0.00
EBITDA	1.35B	1.95B	4.28B	3.25B	2.12B	2.06B	1.85B	1.81B	1.58B	1.18B	1.24B	1.26B	1.18B	1.19B	1.14B	1.04B	990.40M	853.10M	784.80M	790.20M	668.40M	554.30M	471.60M	339.70M	234.20M	211.80M	17.50M	186.70M	139.60M	154.30M	217.70M	227.00M	195.50M	158.80M	126.10M	313.90M
EBITDA Ratio	11.07%	18.44%	25.54%	25.35%	17.04%	18.58%	18.89%	19.50%	18.17%	19.93%	19.17%	20.26%	20.31%	21.49%	21.88%	20.07%	25.49%	23.65%	24.13%	23.78%	22.74%	22.83%	21.82%	17.91%	13.94%	12.97%	-0.50%	0.59%	9.65%	19.98%	26.46%	50.01%	33.07%	32.30%	32.58%	100.00%
Operating Income	725.60M	1.77B	3.26B	2.45B	1.33B	1.33B	1.36B	1.31B	1.00B	910.40M	990.90M	1.02B	948.40M	978.80M	935.90M	842.90M	777.00M	697.10M	618.10M	598.40M	533.70M	435.00M	367.60M	250.10M	149.70M	127.60M	-92.00M	-95.80M	67.20M	109.90M	185.50M	200.10M	173.50M	140.40M	112.80M	313.90M
Operating Income Ratio	5.97%	11.92%	20.22%	17.49%	11.51%	11.70%	13.07%	13.61%	11.55%	15.14%	17.06%	18.05%	17.11%	19.56%	19.94%	18.71%	19.10%	19.41%	18.57%	19.40%	18.16%	17.35%	16.71%	13.03%	8.81%	7.91%	-6.06%	-5.96%	4.69%	12.60%	24.39%	27.74%	28.73%	27.97%	28.03%	100.00%
Total Other Income/Expenses	-156.70M	-199.10M	-132.90M	-226.30M	-225.30M	-57.40M	-227.70M	-206.90M	-270.80M	-83.70M	-75.30M	-79.30M	-82.30M	-63.20M	-51.30M	-57.20M	25.30M	23.80M	22.60M	16.90M	6.70M	-2.70M	-35.30M	-42.50M	-44.20M	-46.10M	-92.00M	-92.50M	-64.10M	-54.50M	5.60M	-138.00M	-4.20M	-3.30M	-5.00M	-313.90M
Income Before Tax	568.90M	1.58B	3.13B	2.22B	1.10B	1.27B	1.13B	1.11B	732.10M	826.70M	915.60M	944.20M	866.10M	915.60M	884.60M	772.40M	802.30M	720.90M	640.70M	615.30M	540.40M	432.30M	332.30M	207.60M	105.50M	81.50M	-161.30M	-188.30M	3.10M	55.40M	191.10M	62.10M	169.30M	137.10M	107.80M	0.00
Income Before Tax Ratio	4.68%	10.64%	19.39%	15.88%	9.56%	11.19%	10.87%	11.47%	8.43%	13.75%	15.76%	16.65%	15.63%	18.30%	18.84%	17.14%	19.72%	20.08%	19.25%	19.95%	18.38%	17.24%	15.11%	10.82%	6.21%	5.05%	-10.62%	-11.71%	0.22%	6.35%	25.13%	8.61%	28.03%	27.32%	26.79%	0.00%
Income Tax Expense	188.50M	302.00M	747.10M	662.10M	280.00M	384.40M	-139.10M	372.30M	294.10M	314.10M	340.20M	359.40M	333.00M	344.00M	329.00M	307.90M	325.50M	289.30M	254.50M	252.30M	219.40M	177.70M	149.60M	95.50M	40.10M	12.70M	-54.40M	-34.80M	7.10M	25.30M	78.40M	21.50M	65.40M	54.50M	43.10M	0.00
Net Income	418.00M	1.28B	2.38B	1.56B	823.80M	883.70M	1.27B	732.10M	436.90M	511.20M	573.80M	583.10M	519.70M	558.20M	543.30M	464.50M	476.80M	431.60M	386.20M	363.00M	321.00M	254.60M	179.50M	112.10M	65.40M	68.80M	-106.90M	-153.50M	-12.30M	30.10M	112.70M	40.60M	103.90M	82.60M	64.70M	0.00
Net Income Ratio	3.44%	8.60%	14.75%	11.13%	7.13%	7.80%	12.15%	7.59%	5.03%	8.50%	9.88%	10.28%	9.38%	11.16%	11.57%	10.31%	11.72%	12.02%	11.61%	11.77%	10.92%	10.15%	8.16%	5.84%	3.85%	4.27%	-7.04%	-9.55%	-0.86%	3.45%	14.82%	5.63%	17.20%	16.46%	16.08%	0.00%
EPS	4.80	14.04	24.58	15.99	8.41	8.71	12.39	7.14	4.42	6.03	6.70	6.24	5.31	5.45	4.98	4.60	4.08	3.48	2.89	2.60	2.23	1.78	1.29	0.83	0.30	0.50	-2.17	-3.12	-0.27	0.90	3.15	1.08	2.63	2.08	1.63	1.25
EPS Diluted	4.77	13.96	24.38	15.88	8.36	8.61	12.21	7.02	4.34	5.91	6.25	5.99	5.11	5.29	4.98	4.60	3.93	3.24	2.71	2.45	2.11	1.77	1.27	0.81	0.29	0.50	-2.17	-3.12	-0.27	0.90	3.15	1.08	2.63	2.08	1.63	1.25
Weighted Avg Shares Out	87.10M	91.10M	96.70M	97.30M	97.90M	101.40M	102.40M	102.50M	98.80M	84.80M	85.70M	93.50M	97.80M	102.40M	109.10M	111.70M	116.86M	124.02M	133.63M	139.62M	143.95M	143.03M	139.15M	52.46M	53.56M	50.40M	49.17M	49.12M	44.73M	33.44M	35.78M	37.77M	39.58M	39.81M	39.82M	39.60M
Weighted Avg Shares Out (Dil)	87.60M	91.60M	97.50M	98.00M	98.60M	102.60M	103.90M	104.30M	100.60M	86.40M	91.80M	97.40M	101.80M	105.40M	109.10M	113.20M	121.32M	133.21M	142.51M	148.16M	152.13M	143.84M	141.34M	56.14M	54.48M	50.40M	49.17M	49.12M	44.73M	34.46M	35.78M	37.77M	39.58M	39.81M	39.82M	39.60M

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

April 2, 2024prnewswire.com

Researchers to present on topics ranging from molecular residual disease and immunotherapy to whole-genome sequencing BURLINGTON, N.C. , April 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will present abstracts in the areas of...

Labcorp (LH) to Boost Clinical Diagnostics With New Deal

April 1, 2024zacks.com

The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.

The Prelude Network® Names Labcorp Its Preferred Genetic Carrier Screening Lab

March 29, 2024prnewswire.com

Expanded partnership to help increase patient access to critical genetic screening services including genetic counseling and test result turnaround time HOUSTON , March 29, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced...

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

March 28, 2024prnewswire.com

Transaction to enhance Labcorp's laboratory services network and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health,...

Labcorp to Announce First Quarter Financial Results on April 25, 2024

March 27, 2024prnewswire.com

BURLINGTON, N.C. , March 27, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the first quarter of 2024 before the market opens on Thursday, April 25, 2024.

Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test

March 25, 2024zacks.com

Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

March 20, 2024prnewswire.com

Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care BURLINGTON, N.C. , March 20, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today...

Labcorp (LH) Presents New Research on Precision Diagnostics

March 18, 2024zacks.com

Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

March 16, 2024prnewswire.com

Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice BURLINGTON, N.C. , March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at...